Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
Peregrine Reports Promising Interim Survival Data From Phase II Cotara Recurrent GBM Trial
TUSTIN, CA–(Marketwire – 05/19/11) – Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM – News ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced interim median overall survival of 8.8 months (38 weeks, 40 patients at first relapse) from a Phase II trial for Cotara in recurrent glioblastoma …
Read more on Marketwire via Yahoo! Finance
Categories: Breast Cancer Information Tags: Cotara, Data, From, Interim, Peregrine, Phase, Promising, recurrent, Reports, Survival, Trial
GTx Provides Corporate Update and Reports 2010 Financial Results
GTx Provides Corporate Update and Reports 2010 Financial Results
MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx provides a corporate update and announces fourth quarter and full year 2010 financial results.
Read more on Business Wire
Categories: Breast Cancer Information Tags: 2010, Corporate, financial, Provides, Reports, Results, Update
TELUS Reports Fourth Quarter 2010 Results
TELUS Reports Fourth Quarter 2010 Results
EPS grows 43 per cent, EBITDA up 7 per cent, free cash flow increases Results driven by growth in wireless subs, ARPU, high-speed Internet, record TV additions VANCOUVER , Feb. 11 /PRNewswire-FirstCall/ – TELUS Corporation reported fourth quarter 2010 revenue of $2.55 billion , an increase of more than four per cent. This increase was generated by nine per cent growth in wireless revenue and …
Read more on redOrbit
Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184
Exelixis Reports Promising Interim Data From Patients With Ovarian Cancer Treated With XL184
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ:EXEL) today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT). Ignace Vergote, M.D., Ph.D., Head of the Department of Obstetrics and Gynaecology and …
Read more on Business Wire
Categories: Metastatic Breast Cancer Tags: cancer, Data, Exelixis, From, Interim, Ovarian, Patients, Promising, Reports, Treated, XL184
Myriad Genetics Reports Fiscal 2011 First Quarter Financial Results
Myriad Genetics Reports Fiscal 2011 First Quarter Financial Results
SALT LAKE CITY — Myriad Genetics, Inc. , a leading molecular diagnostic company, today reported financial results for its first fiscal quarter ended September 30, 2010.
Read more on GlobeNewswire via Yahoo! Finance